ConductScience.org, home

Paper17516689

Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.

Park CH and 6 others. Clin Drug Investig, 2004. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. Papers, record 17516689. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17516689

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.
PubMed
Journal
Clin Drug Investig
PubMed
Year
2004
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
1.41
iCite
Revised in PubMed
2018-11-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Park CHChoal Hee
2Chang HSHyuk Soo
3Oh BRBong Ryul
4Kim HJHyung Jee
5Sul CKChong Koo
6Chung SKSung Kwang
7Jung SISe Il

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17551841Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.Br J Urol1995https://conductscience.org/library/papers/7551841PubMed
27533451Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.Urology1995https://conductscience.org/library/papers/7533451PubMed
31714529High prevalence of benign prostatic hypertrophy in the community.Lancet1991https://conductscience.org/library/papers/1714529PubMed
410559616
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
Eur Urol1999https://conductscience.org/library/papers/10559616PubMed
57536677Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.Eur J Pharmacol1995https://conductscience.org/library/papers/7536677PubMed
688984A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction.Br J Urol1978https://conductscience.org/library/papers/88984PubMed
79609624Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group.Urology1998https://conductscience.org/library/papers/9609624PubMed
87500467Localization of the alpha 1A-adrenoceptor in the human prostate.J Urol1995https://conductscience.org/library/papers/7500467PubMed
98183249The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.Mol Pharmacol1994https://conductscience.org/library/papers/8183249PubMed
1011832780Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction.J Urol2002https://conductscience.org/library/papers/11832780PubMed
119117115The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes.Br J Pharmacol1997https://conductscience.org/library/papers/9117115PubMed
129609623Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.Urology1998https://conductscience.org/library/papers/9609623PubMed
138647140
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Eur Urol1996https://conductscience.org/library/papers/8647140PubMed
149160069Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.South Med J1997https://conductscience.org/library/papers/9160069PubMed
156206240The development of human benign prostatic hyperplasia with age.J Urol1984https://conductscience.org/library/papers/6206240PubMed
167518981Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.Urology1994https://conductscience.org/library/papers/7518981PubMed
178684407The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.N Engl J Med1996https://conductscience.org/library/papers/8684407PubMed
188647141
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Eur Urol1996https://conductscience.org/library/papers/8647141PubMed
1910559631alpha(1)-blockers for BPH: are there differences?Eur Urol1999https://conductscience.org/library/papers/10559631PubMed
209122046Prostatic alpha 1-adrenoceptors and uroselectivity.Prostate1997https://conductscience.org/library/papers/9122046PubMed

See all 24 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
38822877Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention.World J Urol2024https://conductscience.org/library/papers/38822877PubMed
37006221Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia.Urol Ann2023https://conductscience.org/library/papers/37006221PubMed
33425801Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers.Transl Clin Pharmacol2020https://conductscience.org/library/papers/33425801PubMed
32079276Invasome: A Novel Nanocarrier for Transdermal Drug Delivery.Nanomaterials (Basel)2020https://conductscience.org/library/papers/32079276PubMed
31905276A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin Monotherapy.Int Neurourol J2019https://conductscience.org/library/papers/31905276PubMed
30383623Who are suitable for low-dose tamsulosin monotherapy as initial treatment strategy in male patients with lower urinary tract symptoms?Medicine (Baltimore)2018https://conductscience.org/library/papers/30383623PubMed
28361519
Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients.
Int Neurourol J2017https://conductscience.org/library/papers/28361519PubMed
28361510Broaden and Build Up Knowledge Based on Investigative and Clinical Research.Int Neurourol J2017https://conductscience.org/library/papers/28361510PubMed
27260129A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.Med Sci Monit2016https://conductscience.org/library/papers/27260129PubMed
26847294Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study.Yonsei Med J2016https://conductscience.org/library/papers/26847294PubMed
23292598The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.Int Urol Nephrol2013https://conductscience.org/library/papers/23292598PubMed
22986578A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.Prostate Cancer Prostatic Dis2013https://conductscience.org/library/papers/22986578PubMed
22806208Randomized controlled trial of tamsulosin for prevention of acute voiding difficulty after rectal cancer surgery.World J Surg2012https://conductscience.org/library/papers/22806208PubMed
21860769Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.Korean J Urol2011https://conductscience.org/library/papers/21860769PubMed
21785445Effect of tamsulosin on ejaculatory function in BPH/LUTS.Asian J Androl2011https://conductscience.org/library/papers/21785445PubMed
18813219Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.Prostate Cancer Prostatic Dis2009https://conductscience.org/library/papers/18813219PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17516689

GET https://conductscience.org/api/papers/v1/17516689/references?page=2